Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,002
datasets available to search
ShareScore release 0.9.0
Dataset results
2,002 results for “sarcoma”
Set of loom files for three Ewing sarcoma cell lines CHLA9, CHLA10, TC71 profiled with scRNASeq at single cell level
<p>The raw sequence files were published in <a href="https://www.mdpi.com/2072-6694/12/4/948">Miller et al, 2020, Cancers</a> . The files were downloaded and processed using kallisto mapper.</p> <p>The loom files were used to build a <a href="https://doi.org/10.1101/2021.06.14.448414">model of cell cycle with switches</a> and in the development of <a href="https://github.com/csgroen/scycle">scycle Python package</a>.</p>
Dataset related to article "Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression"
<p>This record contains raw data related to article “Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression"</p> <p>Complement has emerged as a component of tumor promoting inflammation. We conducted a systematic assessment of the role of complement activation and effector pathways in sarcomas. <em>C3</em> <sup>-/-</sup>, <em>MBL1/2</em> <sup>-/-</sup> and <em>C4</em> <sup>-/-</sup> mice showed reduced susceptibility to 3-methylcholanthrene sarcomagenesis and transplanted sarcomas, whereas C1q and factor B deficiency had marginal effects. Complement 3a receptor (C3aR), but not C5aR1 and C5aR2, deficiency mirrored the phenotype of <em>C3</em> <sup>-/-</sup> mice. C3 and C3aR deficiency were associated with reduced accumulation and functional skewing of tumor-associated macrophages, increased T cell activation and response to anti-PD-1 therapy. Transcriptional profiling of sarcoma infiltrating macrophages and monocytes revealed the enrichment of MHC II-dependent antigen presentation pathway in C3-deficient cells. In patients, C3aR expression correlated with a macrophage population signature and C3 deficiency-associated signatures predicted better clinical outcome. These results suggest that the lectin pathway and C3a/C3aR axis are key components of complement and macrophage-mediated sarcoma promotion and immunosuppression.</p>
Therapeutic drug monitoring of pazopanib in renal cell carci-noma and soft tissue sarcoma – a systematic review_Primary DATA
<p>Primary dataset of the search made for the systematic review: A systematic search of PubMed and Web of Science databases was conducted using search terms related to pazopanib and TDM. Out of 162 and 225 articles identified, respectively, nine articles were selected for review, as they evaluated treatment outcomes or toxicity concerning drug exposure</p>
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
ClinicalTrials.gov study NCT02601950. IPD Sharing: YES. Countries: 9. Publications: 1.
Palbociclib + Ganitumab In Ewing Sarcoma
ClinicalTrials.gov study NCT04129151. IPD Sharing: YES. Countries: 1. Publications: 1.
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
ClinicalTrials.gov study NCT03899805. IPD Sharing: YES. Countries: 1. Publications: 1.
195 original studies of non-coding RNAs in sarcoma
<p><strong>Background</strong>: Sarcomas comprise approximately 1% of all human malignancies, and treatment resistance is one of the main reasons for poor prognosis. Accumulating evidence suggests that non-coding RNAs, including microRNAs, long non-coding RNAs, and circular RNAs, are important molecules involved in the crosstalk between resistance to chemotherapy, targeted therapy, and radiotherapy via various pathways.</p> <p><strong>Methods</strong>: We searched PubMed (MEDLINE) databases for articles on non-coding RNAs relevant to sarcoma from inception to November 30, 2021. Studies investigating the roles of host-derived microRNAs, long non-coding RNAs, and circular RNAs in sarcoma were included. Data on the roles of ncRNAs in therapeutic regulation and their applicability as biomarkers of sarcomas were extracted. Two independent researchers assessed the quality of the studies using modified guidelines from the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE), a tool based on the Cochrane Collaboration Risk of Bias tool.</p> <p><strong>Results</strong>: Observational studies revealed ectopic expression of non-coding RNAs in sarcoma patients with different responses to antitumor treatments. Experimental studies have confirmed crosstalk between cellular pathways pertinent to chemotherapy, targeted therapy, and radiotherapy resistance. Of the included studies, the SYRCLE scores ranged from 3 to 6 (average score = 4.51). This finding suggested a moderate risk of bias. Of the ten articles that investigated non-coding RNAs as biomarkers, none included a validation cohort. Selective reporting of the sensitivity, specificity, and receiver operating curves was common.</p> <p><strong>Conclusion</strong>: Although non-coding RNAs appear to be good candidates as biomarkers and therapeutics for sarcoma, their differential expression across tissues complicates their application. Further investigation of the potential for inhibition or activation of these regulatory molecules to reverse treatment resistance may be useful.</p>
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
ClinicalTrials.gov study NCT00474994. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg
ClinicalTrials.gov study NCT00589121. IPD Sharing: Not stated. Countries: 2. Publications: 2.
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
ClinicalTrials.gov study NCT01343043. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
ClinicalTrials.gov study NCT01391962. IPD Sharing: YES. Countries: 1. Publications: 4.
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
ClinicalTrials.gov study NCT02573259. IPD Sharing: NO. Countries: 7. Publications: 3.
Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
ClinicalTrials.gov study NCT03526679. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
ClinicalTrials.gov study NCT00642941. IPD Sharing: YES. Countries: 11. Publications: 2.
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
ClinicalTrials.gov study NCT00942877. IPD Sharing: YES. Countries: 1. Publications: 4.
Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas
ClinicalTrials.gov study NCT00996346. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
ClinicalTrials.gov study NCT01141491. IPD Sharing: Not stated. Countries: 1. Publications: 2.
E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma
ClinicalTrials.gov study NCT00413192. IPD Sharing: Not stated. Countries: 5. Publications: 2.
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
ClinicalTrials.gov study NCT01514188. IPD Sharing: Not stated. Countries: 7. Publications: 1.
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
ClinicalTrials.gov study NCT02511132. IPD Sharing: NO. Countries: 1. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.